67 related articles for article (PubMed ID: 11595721)
1. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
Takahashi N; Li WW; Banerjee D; Scotto KW; Bertino JR
Clin Cancer Res; 2001 Oct; 7(10):3251-7. PubMed ID: 11595721
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of new in vitro models and identification of potentially active drugs in angiosarcoma.
Mendiola M; Saarela J; Escudero FJ; Heredia-Soto V; Potdar S; Rodriguez-Marrero S; Miguel M; Pozo-Kreilinger JJ; Berjon A; Ortiz-Cruz E; Feliu J; Redondo A
Biomed Pharmacother; 2024 Apr; 173():116397. PubMed ID: 38479181
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic advances in leiomyosarcoma.
Lacuna K; Bose S; Ingham M; Schwartz G
Front Oncol; 2023; 13():1149106. PubMed ID: 36969049
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells.
Loi M; Salvatore G; Aquilano M; Greto D; Talamonti C; Salvestrini V; Melica ME; Valzano M; Francolini G; Sottili M; Santini C; Becherini C; Campanacci DA; Mangoni M; Livi L
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430780
[TBL] [Abstract][Full Text] [Related]
5. From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.
De Sanctis R; Jacobs F; Benvenuti C; Gaudio M; Franceschini R; Tancredi R; Pedrazzoli P; Santoro A; Zambelli A
Front Pharmacol; 2022; 13():909566. PubMed ID: 36160422
[TBL] [Abstract][Full Text] [Related]
6. Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review.
Asano H; Isoe T; Ito YM; Nishimoto N; Watanabe Y; Yokoshiki S; Watari H
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267488
[TBL] [Abstract][Full Text] [Related]
7. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Saada-Bouzid E; Bertucci F; Bompas E; Alexandre J; Collard O; Lebrun-Ly V; Soulier P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
ESMO Open; 2021 Aug; 6(4):100209. PubMed ID: 34325109
[TBL] [Abstract][Full Text] [Related]
8. Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes.
Barreca M; Spanò V; Montalbano A; Cueto M; Díaz Marrero AR; Deniz I; Erdoğan A; Lukić Bilela L; Moulin C; Taffin-de-Givenchy E; Spriano F; Perale G; Mehiri M; Rotter A; P Thomas O; Barraja P; Gaudêncio SP; Bertoni F
Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33291602
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.
Tun JO; Salvador-Reyes LA; Velarde MC; Saito N; Suwanborirux K; Concepcion GP
Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31527453
[TBL] [Abstract][Full Text] [Related]
10. Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.
El Bairi K; Amrani M; Afqir S
Cancer Med; 2018 Jun; 7(6):2221-2246. PubMed ID: 29732738
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ratan R; Patel SR
Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
[TBL] [Abstract][Full Text] [Related]
12. Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.
Di Napoli M; Della Pepa C; Arenare L; Scambia G; Lorusso D; Raspagliesi F; Ferrandina G; Salutari V; Sorio R; Mosconi AM; Mangili G; Borgato L; Lepori S; Salvino A; Pignata S; Cecere SC
Support Care Cancer; 2017 Jun; 25(6):1743-1748. PubMed ID: 28101677
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.
Nicoletto MO; Baldoni A; Casarin A; Randon G; Nardin M; Baretta Z; Lardelli P; Nieto A; Alfaro V; Rigamonti C; Conte PF
Tumori; 2015; 101(5):506-10. PubMed ID: 26108247
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
von Mehren M; Bookman M; Meropol NJ; Weiner LM; Sherman E; Li J; Knoblauch R; Parekh T; Cohen RB
Cancer Chemother Pharmacol; 2015 May; 75(5):1047-55. PubMed ID: 25791363
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin for advanced soft tissue sarcomas: optimizing use.
Reid A; Martin-Liberal J; Benson C
Ther Clin Risk Manag; 2014; 10():1003-11. PubMed ID: 25540587
[TBL] [Abstract][Full Text] [Related]
16. Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.
Le VH; Inai M; Williams RM; Kan T
Nat Prod Rep; 2015 Feb; 32(2):328-47. PubMed ID: 25273374
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.
Mascilini F; Amadio G; Di Stefano MG; Ludovisi M; Di Legge A; Conte C; De Vincenzo R; Ricci C; Masciullo V; Salutari V; Scambia G; Ferrandina G
Onco Targets Ther; 2014; 7():1273-84. PubMed ID: 25050069
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.
Blay JY; Italiano A; Ray-Coquard I; Le Cesne A; Duffaud F; Rios M; Collard O; Bertucci F; Bompas E; Isambert N; Chaigneau L; Cassier P; Bui B; Decanter G; Derbel O; Coindre JM; Zintl P; Badri N; Penel N
BMC Cancer; 2013 Feb; 13():64. PubMed ID: 23388156
[TBL] [Abstract][Full Text] [Related]
19. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
Gore L; Rivera E; Basche M; Moulder-Thompson SL; Li J; Eppers S; Grolnic S; O'Bryant C; Cleere D; Elsayed YA; Eckhardt SG
Invest New Drugs; 2012 Oct; 30(5):1942-9. PubMed ID: 21931969
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma.
Thornton KA
Core Evid; 2010 Jun; 4():191-8. PubMed ID: 20694075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
